Pfizer (PFE) Stock Analysis 2026: Is It Undervalued Right Now?
Pfizer is one of the most debated stocks on Wall Street right now.
On one side, you have a pharmaceutical giant trading at a fraction of its COVID-era highs, throwing off a 6.46% dividend yield that makes income investors drool. On the other side, you have a company navigating a massive revenue cliff as pandemic products fade, with a payout ratio that is stretched thin.
So which is it — a deep value opportunity or a value trap?
Let us do what we always do here at Poor Man's Stocks: ignore the noise, pull out the numbers, and let the math tell us the truth.
Pfizer at a Glance: Key Metrics (March 2026)
| Metric | Value |
|---|---|
| Stock Price | $26.62 |
| Market Cap | $151.3B |
| Revenue (FY 2025) | $62.58B |
| Net Income (FY 2025) | $7.77B |
| EPS (Diluted) | $1.36 |
| P/E Ratio | 19.57 |
| Forward P/E | ~8.43 (Non-GAAP) |
| Dividend Per Share | $1.72 |
| Dividend Yield | 6.46% |
| Payout Ratio | 126.07% |
| Book Value Per Share | $15.14 |
| Free Cash Flow Per Share | $1.59 |
| 52-Week Range | $23.91 - $31.54 |
| Beta | 0.65 |
Data sourced from StockAnalysis.com and Google Finance as of March 2026.
Revenue Trends: The Post-COVID Reality
Let us be honest about what happened. Pfizer went on an absolute revenue tear during COVID:
| Year | Revenue | YoY Growth |
|---|---|---|
| 2021 | $81.29B | +95.2% |
| 2022 | $101.18B | +24.5% |
| 2023 | $59.55B | -41.1% |
| 2024 | $63.63B | +6.8% |
| 2025 | $62.58B | -1.7% |
The revenue cliff from 2022 to 2023 was brutal — a 41% drop as COVID vaccine and Paxlovid demand cratered. But here is what is important: Pfizer has stabilized.
FY 2025 revenue of $62.58 billion is essentially flat versus FY 2024. The company's non-COVID portfolio posted approximately 6% operational growth in 2025, with international markets performing particularly well. That is the number that matters now — can the core business grow without pandemic tailwinds?
The gross margin tells an encouraging story: 74.33% in FY 2025, up from 58.10% in the post-COVID crash year of 2023. That margin is best-in-class for big pharma and shows Pfizer's pricing power on its core drugs remains intact.
Earnings Per Share: The Recovery Trajectory
EPS has been a rollercoaster:
| Year | EPS (Diluted) | Growth |
|---|---|---|
| 2021 | $3.85 | +226.3% |
| 2022 | $5.47 | +42.1% |
| 2023 | $0.37 | -93.2% |
| 2024 | $1.41 | +281.1% |
| 2025 | $1.36 | -3.6% |
That FY 2023 EPS of $0.37 was the bottom. Pfizer bounced back to $1.41 in 2024 and held at $1.36 in 2025. The slight decline is mostly from one-time charges and restructuring costs — the company is targeting $1.3 billion in net cost savings by 2026.
What matters for value investors: the normalized earnings power of this business. If we strip out pandemic noise, Pfizer is earning roughly $1.36-$1.41 per share on a GAAP basis, with non-GAAP estimates significantly higher (analysts project forward non-GAAP EPS around $3.00-$3.15).
Graham Number Calculation
The Graham Number gives us a quick "maximum fair price" for a stock based on Ben Graham's principles. The formula:
Graham Number = √(22.5 × EPS × Book Value Per Share)
Let us plug in Pfizer's numbers:
- EPS (TTM, Diluted): $1.36
- Book Value Per Share: $15.14
Graham Number = √(22.5 × $1.36 × $15.14)
Graham Number = √($463.54)
Graham Number = $21.53
At today's price of $26.62, Pfizer trades above its Graham Number by about 24%. By this strict Graham metric, PFE is not a screaming bargain.
But wait — and this is important — the Graham Number uses trailing GAAP EPS. Pfizer's GAAP numbers are still depressed by pandemic-era writedowns and restructuring. If we use normalized non-GAAP EPS of ~$3.00:
Adjusted Graham Number = √(22.5 × $3.00 × $15.14) = √($1,022.10) = $31.97
Under that scenario, PFE is trading at a 17% discount to fair value.
This is why context matters more than formulas in isolation. Want to learn more about the math? Check out our How to Calculate Intrinsic Value guide.
Graham Intrinsic Value Formula
Let us also run the growth-based intrinsic value formula:
V = EPS × (8.5 + 2g) × 4.4 / Y
Where:
- EPS = $1.36 (GAAP) or $3.00 (Non-GAAP estimate)
- g = estimated growth rate (analyst consensus: ~5% for next 5 years)
- Y = current AAA corporate bond yield (~5.0%)
Using GAAP EPS: V = $1.36 × (8.5 + 10) × 4.4 / 5.0 V = $1.36 × 18.5 × 0.88 V = $22.14
Using Non-GAAP EPS: V = $3.00 × (8.5 + 10) × 4.4 / 5.0 V = $3.00 × 18.5 × 0.88 V = $48.84
The truth is probably somewhere in between. Pfizer's intrinsic value range: $22-$49, depending on which earnings you trust.
Dividend Analysis: Is That 6.46% Yield Safe?
This is the elephant in the room. Pfizer's headline numbers:
- Annual Dividend: $1.72 per share
- Yield: 6.46%
- Payout Ratio (GAAP): 126.07%
- Consecutive Growth Years: 15
A payout ratio above 100% means the company is paying out more in dividends than it earns. That is unsustainable long-term. But here is the nuance:
Free Cash Flow tells a different story. Pfizer generated $9.08 billion in FCF during FY 2025, or $1.59 per share. The dividend costs $1.72 per share. That is a FCF payout ratio of 108% — still stretched, but much closer to covered.
On a non-GAAP basis, the dividend is comfortably covered. Management has explicitly committed to maintaining the dividend and announced no plans to cut it. The 15-year growth streak is something they clearly want to protect.
Our take: The dividend is safe for now but on a short leash. If revenue declines further or pipeline drugs underperform, a freeze (no increase) is more likely than a cut. For a deeper understanding of what these numbers mean, see our Dividend Payout Ratio Explained guide.
The Bull Case for Pfizer
1. Massive Undervaluation on Non-GAAP Basis At a forward P/E of ~8.4x on non-GAAP earnings, Pfizer is dirt cheap compared to its pharma peers (average 15-18x). Either the market is right that earnings will fall, or this is a screaming buy.
2. Pipeline Is Deep Pfizer has over 100 programs in its pipeline, including promising late-stage candidates in oncology, obesity (GLP-1 arena via Sciwind partnership), and immunology. The $43 billion Seagen acquisition in 2023 gave it a world-class oncology portfolio.
3. Cost Cutting Is Working $1.3 billion in targeted net cost savings by 2026. Gross margins have already recovered to 74%+.
4. The Dividend Is a Magnet A 6.46% yield from a blue-chip with 15 years of consecutive growth attracts income investors. That demand creates a price floor.
5. Obesity Drug Potential The February 2026 deal with Sciwind Biosciences for ecnoglutide (a type 2 diabetes/obesity treatment) shows Pfizer is serious about entering the GLP-1 market — potentially worth hundreds of billions.
The Bear Case for Pfizer
1. Patent Cliff Is Real Key drugs losing patent protection over the next 5 years could strip billions in revenue. This is the single biggest risk.
2. COVID Revenue Is Gone The COVID vaccine/Paxlovid gravy train has left the station. Pfizer needs to replace $40B+ in peak pandemic revenue.
3. Payout Ratio Is Stretched A 126% GAAP payout ratio leaves zero margin for error. One bad quarter could force a dividend freeze or cut.
4. Seagen Integration Risk The massive acquisition needs to deliver. Integration of a $43B deal is never simple.
5. Regulatory Uncertainty FDA leadership concerns (flagged by Pfizer's own CEO in March 2026) and political pressure on drug pricing create headwinds.
Pros and Cons Summary
| Pros | Cons |
|---|---|
| 6.46% dividend yield | 126% GAAP payout ratio |
| Forward P/E of ~8.4x | Patent cliff approaching |
| 74% gross margins | COVID revenue fully gone |
| Deep pipeline (100+ programs) | Seagen integration risk |
| Cost savings on track | Regulatory uncertainty |
| Obesity drug optionality | Revenue essentially flat |
Our Verdict: Cautious Buy with a Price Target of $28-$34
Pfizer is a classic "show me" stock. The value is there on paper — a forward P/E under 9x, a 6%+ yield, and a massive pipeline. But the market will not pay up until Pfizer proves its non-COVID portfolio can grow consistently.
Our price target range: $28-$34 over the next 12 months.
- $28 represents fair value using conservative GAAP-based estimates
- $34 assumes non-GAAP earnings come through and pipeline catalysts hit
At $26.62, you are getting paid 6.46% to wait for the turnaround. That is not a bad deal — as long as you understand you are buying uncertainty, not a sure thing.
Best for: Income investors with a 3-5 year time horizon who can stomach volatility and want high current yield.
Not for: Conservative dividend investors who prioritize payout ratio safety above all else.
How to Buy PFE Stock
Ready to start a position in Pfizer? Here are our recommended brokerages:
Open a Moomoo Account — Get up to 15 free stocks when you deposit. Commission-free trading with professional-grade research tools.
Open a Webull Account — Commission-free stock and ETF trading, plus fractional shares so you can start with any amount.
Both platforms let you set up DRIP (Dividend Reinvestment Plans) to automatically reinvest your Pfizer dividends — the poor man's path to compounding wealth.
Related Tools
- Graham Number Calculator — Calculate the Graham Number for any stock
- Intrinsic Value Calculator — Run the full Graham formula
- Dividend Yield Calculator — Check any stock's yield
- DRIP Calculator — See how reinvesting PFE dividends compounds over time
Disclaimer: This analysis is for educational purposes only and does not constitute financial advice. Always do your own research before making investment decisions. Data accurate as of March 2026.
Get Picks Like This Every Tuesday
Join 10,000+ value investors getting our best undervalued stock picks, Graham Number breakdowns, and dividend analysis — free.
Get Our Best Stock Picks — Free
Join 10,000+ value investors. Get our top undervalued stock picks, Graham-style analysis, and dividend recommendations delivered to your inbox every week.
No spam, ever. Unsubscribe anytime.